Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the long-term efficacy of initiating therapy with metformin/pioglitazone/exenatide in patients with new-onset type 2 diabetes mellitus (T2DM) versus sequential addition of metformin followed by glipizide and insulin. RESEARCH DESIGN AND METHODS: Drug-naive patients (N = 318) with new-onset T2DM were randomly assigned to receive for 3 years either 1) combination therapy with metformin, pioglitazone, and exenatide (triple therapy) or 2) sequential addition of metformin followed by glipizide and insulin (conventional therapy) to maintain HbA1c at <6.5% (48 mmol/mol). Insulin sensitivity and β-cell function were measured at baseline and 3 years. The primary outcome was the difference in HbA1c between the groups at 3 years. RESULTS: Baseline HbA1c ± SEM values were 9.0% ± 0.2% and 8.9% ± 0.2% in the triple therapy and conventional therapy groups, respectively. The decrease in HbA1c resulting from triple therapy was greater at 6 months than that produced by conventional therapy (0.30% [95% CI 0.21–0.39]; P = 0.001), and the HbA1c reduction was maintained at 3 years in patients receiving triple therapy compared with conventional therapy (6.4% ± 0.1% and 6.9% ± 0.1%, respectively), despite intensification of antihyperglycemic therapy in the latter. Thus, the difference in HbA1c between the two treatment groups at 3 years was 0.50% (95% CI 0.39–0.61; P < 0.0001). Triple therapy produced a threefold increase in insulin sensitivity and 30-fold increase in β-cell function. In conventional therapy, insulin sensitivity did not change and β-cell function increased by only 34% (both P < 0.0001 vs. triple therapy). CONCLUSIONS: Triple therapy with agents that improve insulin sensitivity and β-cell function in patients with new-onset T2DM produces greater, more durable HbA1c reduction than agents that lower glucose levels without correcting the underlying metabolic defects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acarbose has been shown to lower A1C and cause weight loss.1056,1057”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1056]
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 2×
“OGTT-derived indices of insulin sensitivity and insulin secretion were calculated from the PG, insulin, and C-peptide (C-pep) concentrations during the OGTT, as previously described (5,20,21).”
MethodSelf-citationDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 1×
“95 SD) HbA1c difference between the two treatment arms based on the HbA1c decrease in the PROactive study (22).”
MethodDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationThe Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Self-citationAhlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Warram, J. H., Martin, B. C., Krolewski, A. S., Soeldner, J. S., & Kahn, C. R. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-12-909 · Cited by 1,038
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540
Self-citationAbdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes · doi:10.2337/db05-1200 · Cited by 500
Self-citationBeta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2004) · Diabetologia · doi:10.1007/s00125-003-1263-9 · Cited by 338
Self-citationGulli, G., Ferrannini, E., Stern, M., Haffner, S., & DeFronzo, R. A. (1992) · Diabetes · doi:10.2337/diab.41.12.1575 · Cited by 283
Self-citationMontvida, O., Shaw, J., Atherton, J. J., Stringer, F., & Paul, S. K. (2018) · Diabetes Care · doi:10.2337/dc17-1414 · Cited by 250
Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240
Abdul‐Ghani, M. A., Puckett, C., Triplitt, C., Maggs, D., Adams, J., Cersosimo, E., & DeFronzo, R. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12417 · Cited by 208 · cited 4×
“The combination of pioglitazone plus GLP-1 RA is very effective in lowering HbA1c in patients with new-onset diabetes (17), as well as in patients with poorly controlled T2DMwho have longstanding disease (18).”
BackgroundMethodInfluentialSelf-citationThiazolidinediones improve β-cell function in type 2 diabetic patients
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00551.2006 · Cited by 200
Self-citationInadequate β-cell mass is essential for the pathogenesis of type 2 diabetes
Weir, G. C., Gaglia, J., & Bonner-Weir, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30022-x · Cited by 194
In Vivo Actions of Peroxisome Proliferator–Activated Receptors
Eldor, R., DeFronzo, R. A., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2003 · Cited by 126
Self-citationPrevention of Diabetes With Pioglitazone in ACT NOW
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Gastaldelli, A., Henry, R. R., Kitabchi, A. E., et al. (2013) · Diabetes · doi:10.2337/db13-0265 · Cited by 109 · cited 6×
“After screening, eligible participants underwent 1) a 75-g oral glucose tolerance test (OGTT) and 2) ultrasound measurement of carotid intima-media thickness (CIMT) (15).”
BackgroundMethodInfluentialSelf-citationLe, P., Chaitoff, A., Misra-Hebert, A. D., Ye, W., Herman, W. H., & Rothberg, M. B. (2020) · Diabetes Care · doi:10.2337/dc19-2424 · Cited by 82
Abdul-Ghani, M., & DeFronzo, R. A. (2017) · Diabetes Care · doi:10.2337/dc16-2368 · Cited by 62
Self-citationAbdul-Ghani, M., Migahid, O., Megahed, A., Adams, J., Triplitt, C., DeFronzo, R. A., Zirie, M., & Jayyousi, A. (2017) · Diabetes Care · doi:10.2337/dc16-1738 · Cited by 39 · cited 1×
“The combination of pioglitazone plus GLP-1 RA is very effective in lowering HbA1c in patients with new-onset diabetes (17), as well as in patients with poorly controlled T2DMwho have longstanding disease (18).”
BackgroundSelf-citationLawrence, J. M., Slezak, J. M., Li, X., Yu, L., Rewers, M., Takhar, H. S., Sridhar, S. B., VEGA-DAILY, L. I., Alexander, J., Ritchie, J. L., et al. (2019) · Diabetes · doi:10.2337/db19-1670-p · Cited by 24
Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c
Abdul-Ghani, M. A., Migahid, O., Megahed, A., DeFronzo, R. A., Zirie, M. A., & Jayyousi, A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3423 · Cited by 15 · cited 1×
“Furthermore, the combination of pioglitazone plus GLP-1 RA effectively reduces HbA1c independent of the starting HbA1c level (17,19).”
BackgroundSelf-citation
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationSamson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Sibony, R. W., Segev, O., Dor, S., & Raz, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417147 · Cited by 166
Metadata
- Authors
- Abdul-Ghani, M., Puckett, C., Adams, J., Khattab, A., Baskoy, G., Cersosimo, E., Triplitt, C., & DeFronzo, R. A.
- Affiliations
- Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, TX
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-03
- Volume
- 44
- Issue
- 2
- Pages
- 433-439
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7818318
- OpenAlex
- W3107469749
- Cited by
- 55
- References
- 26
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 14 · 2023: 10 · 2022: 13 · 2021: 5
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R01DK24092-34)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- triple combination therapy, metformin, pioglitazone, exenatide, glipizide, insulin therapy, HbA1c reduction, insulin sensitivity, beta-cell function, antihyperglycemic therapy
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Metformin, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.